Asset Details
Do you wish to reserve the book?
Vascular Risk Factors and Diabetic Neuropathy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Vascular Risk Factors and Diabetic Neuropathy
Do you wish to request the book?
Vascular Risk Factors and Diabetic Neuropathy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Vascular Risk Factors and Diabetic Neuropathy
2005
Overview
Apart from glycemic control, there is no treatment for diabetic neuropathy. Thus, identifying potentially modifiable risk factors is crucial for the development of new therapies.
In addition to glycemic control, the incidence of neuropathy in type 1 diabetes is associated with potentially modifiable cardiovascular risk factors including a raised triglyceride level, body-mass index, smoking, and hypertension.
Diabetic neuropathy is a common cause of morbidity and death among patients with diabetes, generating a huge economic burden.
1
Apart from tight glycemic control, no other evidence-based treatments are known to ameliorate or prevent neuropathy.
The duration and level of hyperglycemia are important determinants of microvascular complications of diabetes, including neuropathy.
2
The relative effect of cardiovascular risk factors specifically associated with diabetes (e.g., hypertension, dyslipidemia, and increased weight) or not associated with diabetes (smoking) on the development of neuropathy are incompletely elucidated. The Diabetes Control and Complications Trial (DCCT) reported a 60 percent reduction in neuropathy in the intensively treated . . .
Publisher
Massachusetts Medical Society
Subject
/ Biological and medical sciences
/ Cardiovascular Diseases - complications
/ Diabetes
/ Diabetes Mellitus, Type 1 - blood
/ Diabetes Mellitus, Type 1 - complications
/ Diabetes. Impaired glucose tolerance
/ Diabetic Neuropathies - diagnosis
/ Diabetic Neuropathies - etiology
/ Endocrine pancreas. Apud cells (diseases)
/ Etiopathogenesis. Screening. Investigations. Target tissue resistance
/ Female
/ Glycated Hemoglobin A - metabolism
/ Humans
/ Male
/ Patients
